Table 3.
Association between serum miR-25 level and clinicopathological characteristics in patients with PCa.
| Serum miR-25 | |||
| Variables | n | Median | P value |
| Total | 80 | 5085.75 | |
| Gender | |||
| Female | 40 | 4497.19 | .181 |
| Male | 40 | 5545.68 | |
| Ages, years | |||
| ≤65 | 53 | 5203.74 | .733 |
| >65 | 27 | 4745.60 | |
| Tumor location | |||
| Phn | 40 | 5429.19 | .326 |
| Pbt | 40 | 4497.19 | |
| T-stage | .031 | ||
| T1/T2 | 45 | 4510.03 | |
| T3/T4 | 35 | 5949.15 | |
| N-stage | .421 | ||
| N0 | 40 | 4781.06 | |
| N1/Nx | 40 | 5107.85 | |
| M-stage | .197 | ||
| M0 | 62 | 4784.04 | |
| M1 | 18 | 5810.25 | |
| CEA | .388 | ||
| <5.2 | 54 | 4907.60 | |
| ≥5.2 | 26 | 5762.85 | |
| CA125 | .143 | ||
| <35 | 58 | 4731.36 | |
| ≥35 | 22 | 5528.50 | |
| TBIL | .147 | ||
| <17.1 | 47 | 4683.75 | |
| ≥17.1 | 33 | 5232.73 | |